Sigyn Therapeutics (SIGY) Change in Accured Expenses (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Change in Accured Expenses of $524.0 for Q3 2025, down 88.85% sequentially from $4698.0 in Q2 2025, and up 113.78% YoY from $245.11 in Q3 2024.
Sigyn Therapeutics (SIGY) Change in Accured Expenses (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Change in Accured Expenses for 10 years, with the latest figure at $524.0 in Q3 2025.
- Quarterly Change in Accured Expenses rose 113.78% year-over-year to $524.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $2280.0 (up 134.25% YoY) and the FY2024 annual result came in at -$6906.0, down 460.1% from the prior year.
- Change in Accured Expenses eased to $524.0 in Q3 2025 per SIGY's latest filing, from $4698.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $42666.0 in Q3 2021 and troughed at -$20089.0 in Q4 2021.
- A 5-year average of $1116.3 and a median of $90.0 in 2024 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 378.38% in 2024, then soared 404.08% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$20089.0 in 2021, then soared by 102.66% to $534.0 in 2022, then sank by 36.52% to $339.0 in 2023, then sank by 73.45% to $90.0 in 2024, then jumped by 482.22% to $524.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $524.0, $4698.0, and -$3032.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 524.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 524.00 |
| Sep 30, 2025 | 524.00 |
| Jun 30, 2025 | 4,698.00 |
| Jun 30, 2025 | 4,698.00 |
| Mar 31, 2025 | -3,032.00 |
| Mar 31, 2025 | -3,032.00 |
| Dec 31, 2024 | 90.00 |
| Dec 31, 2024 | 90.00 |
| Sep 30, 2024 | -3,803.00 |
| Sep 30, 2024 | -3,803.00 |
| Jun 30, 2024 | -1,545.00 |
| Jun 30, 2024 | -1,545.00 |
| Mar 31, 2024 | -1,648.00 |
| Mar 31, 2024 | -1,648.00 |
| Dec 31, 2023 | 339.00 |
| Dec 31, 2023 | 339.00 |
| Sep 30, 2023 | -1,487.00 |
| Sep 30, 2023 | -1,487.00 |
| Jun 30, 2023 | 555.00 |
| Jun 30, 2023 | 555.00 |